Cambium Bio Limited Secures AUD 1.008 Million via Placement of 2.1 Million Shares on ASX

Details of Capital Raise and Issuance Process

Cambium Bio Limited completed a capital raise through the placement of 2.1 million fully paid ordinary shares, formally announced to the ASX on 22 July 2026 and finalized on 24 July 2026. The shares were issued at AUD $0.48 each, raising gross proceeds of AUD $1.008 million. This discrete fundraising event has now progressed to the quotation stage, enabling trading of the new shares on the ASX.

The placement was conducted as a cash consideration raise in Australian dollars, with all shares carrying standard voting and dividend rights. The AUD $0.48 issue price reflects the agreed valuation between Cambium Bio and participating investors. No further securities need to be issued to complete this transaction, confirming full subscription and receipt of committed funds.

Growth of Issued Capital and Shareholder Structure

The addition of 2.1 million shares significantly increases Cambium Bio Limited’s issued capital on the ASX. Following quotation, the company’s total ordinary fully paid shares will reach 29,431,918, representing a notable expansion of its equity base and enhancing liquidity for investors. This issuance reflects strong investor demand and supports the company’s funding requirements for operational and strategic initiatives.

Alongside the quoted shares, Cambium Bio holds 623,629 unquoted options with various expiry dates and exercise prices. These options constitute contingent equity interests that may convert to ordinary shares upon exercise, subject to respective terms. Together, the quoted shares and unquoted options define the company’s current capital structure.

Transaction Timeline and ASX Compliance

The capital raise was first disclosed via an Appendix 3B (Proposed Issue of Securities) lodged with the ASX on 22 July 2026 at 08:46 AM, providing market transparency ahead of issuance. The shares were issued on 24 July 2026, with an immediate Appendix 2A (Application for Quotation of Securities) filing requesting official ASX quotation.

This swift transition from announcement to issuance and quotation aligns with ASX regulatory requirements, ensuring continuous market disclosure and enabling investors to trade the new shares promptly. The completion of this process formalizes the capital raise and integrates the new shares into the ASX market alongside existing capital.

Cash-Based Placement and Currency Details

The placement was executed as a cash consideration raise, with funds remitted in Australian dollars at AUD $0.48 per share. Total capital raised amounted to AUD $1.008 million, calculated by multiplying 2.1 million shares by the issue price. This straightforward cash-for-shares transaction provides immediate liquidity for Cambium Bio’s operational and strategic needs.

Pricing the placement in AUD aligns the raise with the domestic market, avoiding foreign exchange risks or complex payment arrangements. The AUD $0.48 price point was mutually agreed with investors and serves as a clear market valuation reference relative to the company’s trading history.

Investor Distribution and Shareholder Base Transparency

As part of the Appendix 2A filing, Cambium Bio provided a distribution schedule categorizing new shareholdings across five brackets: 1–1,000 shares; 1,001–5,000 shares; 5,001–10,000 shares; 10,001–100,000 shares; and over 100,001 shares. While specific percentages were not publicly disclosed, this data was submitted to the ASX in compliance with listing rules.

This distribution information helps assess whether the placement attracted institutional investors, retail participants, or a combination thereof. A broad distribution suggests strong market demand and reduced concentration risk, whereas concentration among larger investors may indicate strategic partnerships. The ASX uses this data to evaluate liquidity and shareholder diversity post-placement.

Cambium Bio Limited’s Market Position and Capital Needs

Cambium Bio Limited, an Australian biotech company, raised AUD $1.008 million to support its ongoing research, development, and commercialisation activities. Operating in a capital-intensive sector, the company requires substantial funding ahead of revenue generation or milestone achievements. This placement demonstrates investor confidence in Cambium Bio’s strategic direction and pipeline.

Following this raise, the company’s quoted capital totals 29,431,918 ordinary shares, with the 2.1 million new shares representing approximately 7.1% dilution to existing shareholders. This dilution level aligns with typical biotech capital raises balancing funding needs and shareholder interests. The presence of 623,629 unquoted options also reflects the company’s use of equity incentives to align management and employee interests with shareholder value.

Biotech Sector Capital Trends and Investor Sentiment

The successful AUD $1.008 million placement at AUD $0.48 per share highlights sustained investor interest in Australian biotech firms despite sector volatility. Capital raises are critical to finance multi-year R&D efforts prior to revenue or commercial validation. Investor participation signals confidence in Cambium Bio’s strategy and asset pipeline.

The AUD $0.48 placement price offers a market benchmark valuation, influenced by recent share price trends and sector sentiment. Investors and analysts may compare this price against current and historical trading levels to evaluate valuation attractiveness or dilution impact.

Unquoted Options and Potential Dilution

In addition to 29,431,918 quoted shares, Cambium Bio holds 623,629 unquoted options with varying exercise prices and expiration dates. These options grant holders rights to acquire shares under specified conditions, representing potential future dilution if exercised. The options likely form part of employee and management incentive schemes designed to foster long-term value creation.

Should all options be exercised, the total ordinary shares outstanding would increase by 623,629, diluting existing shareholders accordingly. The staggered expiry dates and exercise prices suggest multiple incentive tranches aligned with performance or tenure milestones.

ASX Listing Rules Compliance and Market Transparency

Cambium Bio’s filings of Appendix 3B and Appendix 2A demonstrate adherence to ASX Listing Rules governing capital raises. The Appendix 3B notified the market of the proposed securities issuance, while the Appendix 2A application secured formal quotation. This process ensures continuous disclosure and regulatory compliance, enabling transparent market access to the new shares.

The timing of filings—announcement on 22 July, issuance and quotation application on 24 July—reflects standard ASX practices for efficient capital raise execution while maintaining investor transparency. The new shares are now officially tradable on the ASX, providing full price discovery and liquidity.

Strategic Outlook and Capital Deployment

The AUD $1.008 million capital injection equips Cambium Bio Limited to advance its operational and strategic goals. Typically, biotech firms allocate such funds toward R&D, clinical trials, regulatory processes, manufacturing scale-up, market expansion, or working capital. The company will disclose capital deployment and milestone progress through regular ASX and shareholder reporting.

This successful placement may also enhance Cambium Bio’s capacity for future capital raises or strategic partnerships by broadening its shareholder base and increasing public float. The company may focus on achieving revenue or regulatory milestones that support higher valuations in subsequent funding rounds. Investors should monitor quarterly updates and announcements to gauge progress and capital management following this raise.